Drug intelligence / Profile preview

EB03

Development stage: Preclinical
Lead developer: Edesa Biotech
Administration: Rectal, Topical

Overview

EB03 is a pharmaceutical product under development by Edesa Biotech for human therapeutic use in the conditions of hemorrhoids and anal fissures. Edesa Biotech is responsible for its development for the U.S. market. Pendopharm, a division of Pharmascience, holds an exclusive license to commercialize EB03 in Canada, where it will be responsible for regulatory approval and all commercialization activities.

Beyond the preview

Go deeper on EB03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB03.

Explore the full profile